Transdermal Drug Controller With Microneedle Latching Mechanism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current transdermal drug delivery systems using microneedle assemblies face challenges in achieving a balance between steady-state drug concentration and variable administration rates, particularly for drugs like insulin, where conventional subcutaneous delivery methods result in spikes in bioavailability.
Innovation Solution
A drug delivery apparatus featuring a microneedle assembly integrated with a controller and cartridge system, where the microneedle array is activated by a push-button mechanism, allowing for controlled penetration and fluid communication with a reservoir, enabling precise and sustained drug delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional subcutaneous delivery methods are used, then large amounts of drug can be delivered at one time, but this creates spikes in bioavailability which is problematic for drugs like insulin
Solution Approach 1:
The patent segments the drug delivery process into multiple microneedle units that can deliver drug in controlled, divided amounts rather than a single large dose, helping to avoid bioavailability spikes while maintaining stable concentration levels
Solution Approach 2:
The controller enables dynamic adjustment of drug delivery rates, allowing the system to transition from static bulk delivery to dynamic controlled delivery, thereby stabilizing bioavailability by preventing sudden large doses
2Stability of the object's composition
If transdermal drug delivery apparatus are used to administer drugs at constant rates, then steady state concentration can be achieved, but the system lacks flexibility for variable administration rates
Solution Approach 1:
The controller is designed to be dynamically adjustable, allowing operators to modify delivery rates and parameters in real-time, thus achieving both steady state concentration stability and the flexibility to adapt to varying clinical requirements
Solution Approach 2:
The system enables parameter changes in drug delivery rates through the controller interface, allowing transition between constant and variable rate delivery modes to balance steady state achievement with administrative flexibility
3Object-affected harmful factors
If microneedle assemblies are used, then patient pain is reduced compared to conventional needles, but control over penetration and delivery timing is compromised
Solution Approach 1:
The microneedle assembly is designed to self-penetrate the skin upon application, eliminating the need for manual penetration control while maintaining patient comfort, with the controller subsequently managing the drug delivery timing and rate
Data Source
Figure 1~3
Figure 4~5
Figure 6~7
AI summary
A controller, which may be used in a transdermal drug delivery apparatus, includes a housing, a pushing mechanism mounted for moving relative to the housing, a force provider positioned between the housing and the pushing mechanism for moving the pushing mechanism relative to the housing, and a latching mechanism for selectively restricting and allowing relative movement between the housing and the pushing mechanism. The pushing mechanism may be configured for pushing against a reservoir of the transdermal drug delivery apparatus. The latching mechanism may include flexible arms extending between the opposite ends of the latching mechanism, and the latching mechanism may be configured so that the arms release the pushing mechanism in response to the opposite ends being forced toward one another.